Today, Pfizer announced that it received a Complete Response Letter (CRL) from the FDA in response to Pfizer’s application for its proposed biosimilar of Herceptin® (trastuzumab). According to Pfizer’s press release, the CRL “highlighted the need for additional technical information,” but the “requested information does not relate to safety or clinical data submitted in the application.” Pfizer states that it is “working closely with the FDA to address the contents of the letter and remains committed to bringing this important medicine to patients in the U.S.”

As previously reported, Pfizer is currently engaged in patent litigation under the BPCIA against Genentech regarding its aBLA for this biosimilar candidate. Genentech originally asserted 40 patents in its complaint, but last month stipulated to dismiss half of those patents and filed an amended complaint alleging infringement of the remaining 20 patents. Pfizer answered the amended complaint on April 11, 2018.

Featured Editor

Updated Guide to the Biosimilars Patent Dance

In-house attorneys and executives can request a gratis copy of Goodwin's updated Guide to the Biosimilars Patent Dance

Biosimilars Regulatory IP Guide

Biosimilars: A Guide to Regulatory and Intellectual Property Issues

Subscribe

Big Molecule Watch Monthly DigestMonthly Digest provides analyses on regulatory issues, litigation, legislation, and other news in the ever-developing world of biosimilars. Subscribe>>

Get Real Time Blog PostsYou will receive a verification email once you submit this form to activate your real time Feedburner email subscription to Goodwin Procter - Big Molecule Watch Blog. Subscribe>>